Personal information

Verified email domains

Biography

My career has focused on the biochemistry, pharmacology and therapeutics of human pathogens most notably Plasmodium falciparum and Mycobacterium tuberculosis. Basic biochemical research includes the characterisation of bioenergetic components in the respiratory chain and of key substrate and drug transporters. This fundamental work has contributed to the understanding of mechanisms of drug action, major resistance mechanisms in malaria and validation of novel targets for chemotherapy in both malaria and TB.

Now spanning some 25 years, my research has been supported by three personal fellowships and grant funding from major funders (e.g. Leverhulme, Wellcome, MRC, EU, Innovate UK, NHIR) in excess of £30 million. I have published > 100 peer-review publications, as well as patents for the discovery of novel malaria and anti-tubercular inhibitors. My translational research experience in infection pharmacology and drug discovery/development spans from the development of HTS campaigns to candidate declaration. I have also been involved in the development of several enabling platforms, such as image-based pharmacodynamic (PD) host-pathogen cellular and infection-organoid platforms to identify and accelerate antimalarial, antitubercular and anti-viral pre-clinical drug candidates.

The overarching philosophy of my work is to strive to make scientific research contributions that have the potential to be translated to solutions that have a material impact on the health and well-being of people from resource poor settings. Towards this goal, I have worked in, and collaborated with, partners from LMICs, including Malawi, Rwanda, Kenya, Vietnam and Thailand, and established long-standing collaborations with pharma industry (e.g. GSK DDW Madrid, Astra Zeneca) and relevant product development partnership organisations (PDPs) e.g. Medicines for Malaria Venture (MMV) and the TB Alliance (TBA).

In the UK, I have led efforts to develop and promote a translational research environment for Global Health, including the training of the next generation of research leaders. I led the establishment of the Tropical Infectious Disease Consortium, a partnership between leading UK institutes involved in translational research in tropical infectious diseases (and includes LSTM, the London School of Hygiene and Tropical Medicine, Oxford University and the UK Health Security Agency).

I also established and lead the MRC Translational and Quantitative Skills Doctoral Training Programme in Global Health, a collaboration between LSTM and Lancaster University, that has funded and supported over 50 PhD studentships for the development of the next cadre of future leaders in translational Global Health.
Giancarlo received a UKRI Innovation Scholars personal award in 2021 for the development of sustainable academic-industry partnerships and has an active portfolio of projects with regional and national SMEs towards untapping breakthrough innovation for the treatment and management of infectious diseases.

In 2024, as Director of the Centre for Drugs and Diagnostics (CDD) at LSTM, I spearhead the strategic E3 investment of £9.8 million from Research England for the development of a skilled multi-disciplinary workforce, prioritising Early Career Researchers and disruptive technologies to pioneer innovative solutions for infectious diseases.

Activities

Employment (11)

Liverpool School of Tropical Medicine: Liverpool, Liverpool, GB

2023-09-01 to present | Pro Vice-Chancellor for Research and Innovation (Professor) (Directorate)
Employment
Source: Self-asserted source
Giancarlo Biagini

Liverpool School of Tropical Medicine: Liverpool, GB

2020-05 to 2023-08 | Head of Department (Tropical Disease Biology)
Employment
Source: Self-asserted source
Giancarlo Biagini

Liverpool School of Tropical Medicine: Liverpool, GB

2018-08 to 2020-05 | Deputy Head of Department (Tropical Disease Biology)
Employment
Source: Self-asserted source
Giancarlo Biagini

Liverpool School of Tropical Medicine: Liverpool, GB

2014-08 to 2018-08 | Professor (Parasitoloy)
Employment
Source: Self-asserted source
Giancarlo Biagini

Liverpool School of Tropical Medicine: Liverpool, GB

2011-08 to 2014-07 | Reader (Parasitology)
Employment
Source: Self-asserted source
Giancarlo Biagini

Liverpool School of Tropical Medicine: Liverpool, GB

2008-10 to 2011-07 | Senior Lecturer ( Molecular & Biochemical Parasitology)
Employment
Source: Self-asserted source
Giancarlo Biagini

Liverpool School of Tropical Medicine: Liverpool, GB

2006-05 to 2008-10 | Lecturer (Molecular & Biochemical Parasitology)
Employment
Source: Self-asserted source
Giancarlo Biagini

Liverpool School of Tropical Medicine: Liverpool, GB

2004-10 to 2006-05 | Early Career Leverhulme Trust Fellow (Invited position) ( Molecular & Biochemical Parasitology)
Employment
Source: Self-asserted source
Giancarlo Biagini

Liverpool School of Tropical Medicine: Liverpool, GB

2001-10 to 2004-10 | Postdoctoral Associate ( Molecular & Biochemical Parasitology)
Employment
Source: Self-asserted source
Giancarlo Biagini

University of Cambridge: Cambridge, Cambridgeshire, GB

2000-12 to 2001-06 | Postdoc (Pharmacology)
Employment
Source: Self-asserted source
Giancarlo Biagini

University of New South Wales: Sydney, NSW, AU

1998-02 to 2000-04 | Postdoc (Biochemistry)
Employment
Source: Self-asserted source
Giancarlo Biagini

Education and qualifications (3)

University of Chester: Chester, GB

2021 to present (PGCert in Business Administration (Ongoing))
Qualification
Source: Self-asserted source
Giancarlo Biagini

Cardiff University: Cardiff, South Glamorgan, GB

1998 to present | PhD (Biology)
Qualification
Source: Self-asserted source
Giancarlo Biagini

Cardiff University: Cardiff, South Glamorgan, GB

1994 to present | BSc (Hons) First Class (Biology)
Qualification
Source: Self-asserted source
Giancarlo Biagini

Professional activities (15)

Medical Research Council: London, GB

2024 to present | Invited Panel Member (DPFS Board)
Service
Source: Self-asserted source
Giancarlo Biagini

Medical Research Council: London, London, GB

2018-12 to present | MRC Newton Fund UK-Indonesia Joint Partnership review panel member
Service
Source: Self-asserted source
Giancarlo Biagini

Medical Research Council: London, London, GB

2018-11 to present | MRC Newton Fund Newton UK-Sao Paulo/Brazil review panel member
Service
Source: Self-asserted source
Giancarlo Biagini

Medicines for Malaria Venture: Geneva, CH

2017-12 to present | Enabling Technologies Panel Member
Service
Source: Self-asserted source
Giancarlo Biagini

Medical Research Council: London, London, GB

2017 to present | MRC Newton Fund UK-Vietnam Review Panel member
Service
Source: Self-asserted source
Giancarlo Biagini

Liverpool School of Tropical Medicine: Liverpool, Liverpool, GB

2014 to present | Director (Centre for Drugs & Diagnostics Research (CDDR))
Invited position
Source: Self-asserted source
Giancarlo Biagini

British Society for Antimicrobial Chemotherapy: Birmingham, GB

2011 to present | Editor for Journal of Antimicrobial Chemotherapy
Membership
Source: Self-asserted source
Giancarlo Biagini

Japan Agency for Medical Research and Development: Tokyo, JP

2022 to 2022 (Review Panel)
Service
Source: Self-asserted source
Giancarlo Biagini

Volkswagen Foundation: Hannover, DE

2021 to 2021 | Panel member (Innovative approaches to drug development)
Service
Source: Self-asserted source
Giancarlo Biagini

Japan Agency for Medical Research and Development: Tokyo, JP

2021 to 2021 (Review Panel)
Service
Source: Self-asserted source
Giancarlo Biagini

Medicines for Malaria Venture: Genève, CH

2020 to 2020 (Scientific Advisory Board - Clinical Development of Tafenoquine)
Service
Source: Self-asserted source
Giancarlo Biagini

COST (European cooperation in science and technology) / COST (Europos bendradarbiavimas moksle ir: Brussels, BE

2020 to 2020 | External Expert (Review and Rapporteur) (Open Call OC - 2020)
Service
Source: Self-asserted source
Giancarlo Biagini

Biochemical Society: London, London, GB

2011 to 2016 | Theme Panel member
Service
Source: Self-asserted source
Giancarlo Biagini

Medical Research Council of Norway: Oslo, NO

2014 to 2014 | • Expert International Referee Panel, Global Health and Vaccination Programme (GLOBVAC)
Service
Source: Self-asserted source
Giancarlo Biagini

Liverpool School of Tropical Medicine: Liverpool, Liverpool, GB

2004-10 to 2006-05 | Early Career Leverhulme Trust Fellow
Invited position
Source: Self-asserted source
Giancarlo Biagini

Funding (34)

ICF: Lead Optimisation of a Series of Antimalarial Plasmepsin IX/X Beta-hydroxyethylamine Based Inhibitors

2024-02-01 to 2026-01-31 | Grant
Medical Research Council (London, GB)
GRANT_NUMBER: MR/Y008774/1
Source: Self-asserted source
Giancarlo Biagini via DimensionsWizard

A Pre-clinical Pipeline for Avian Influenza Therapeutics

2024 to 2025 | Grant
Pandemic Institute (-, GB)
Source: Self-asserted source
Giancarlo Biagini

SimCell OPA

2024 to 2025 | Grant
SimCell (-, GB)
Source: Self-asserted source
Giancarlo Biagini

Efficacy of anti-viral materials

2024 to 2024 | Grant
Virustatic (-, GB)
Source: Self-asserted source
Giancarlo Biagini

Novel immunomodulatory therapeutic strategies to target intracellular pathogens

2023-10-01 to 2027-09-30 | Grant
Medical Research Council (London, GB)
GRANT_NUMBER: 2881974
Source: Self-asserted source
Giancarlo Biagini via DimensionsWizard

MRC IAA 2021 Liverpool School of Tropical Medicine

2022-03-31 to 2026-03-30 | Grant
Medical Research Council (London, GB)
GRANT_NUMBER: MR/X502911/1
Source: Self-asserted source
Giancarlo Biagini via DimensionsWizard

Epistatis and antimicrobial drug resistance in tuberculosis

2021-10-03 to 2025-09-29 | Grant
Medical Research Council (London, GB)
GRANT_NUMBER: 2665108
Source: Self-asserted source
Giancarlo Biagini via DimensionsWizard

In vitro models of Neisseria gonorrhoeae infection to study resistance acquisition and inform the selection of novel treatment strategies.

2021-10-02 to 2025-10-01 | Grant
Medical Research Council (London, GB)
GRANT_NUMBER: 2809907
Source: Self-asserted source
Giancarlo Biagini via DimensionsWizard

MICA: Defining the two-step relay mechanism of action of the 8-aminoquinolines: A precondition for optimal combination therapies for relapse malaria

2021-09-05 to 2024-09-04 | Grant
Medical Research Council (London, GB)
GRANT_NUMBER: MR/W002248/1
Source: Self-asserted source
Giancarlo Biagini via DimensionsWizard

Development of sustainable academic-industry partnerships: Untapping breakthrough innovation for the treatment and management of infectious diseases

2021-06-30 to 2024-06-29 | Grant
UK Research and Innovation (Swindon, GB)
GRANT_NUMBER: MR/W004356/1
Source: Self-asserted source
Giancarlo Biagini via DimensionsWizard

UKRI COVID19 Doctoral Funding Liverpool School of Tropical Medicine

2021-03-31 to 2022-03-30 | Grant
Natural Environment Research Council (Swindon, GB)
GRANT_NUMBER: NE/W502662/1
Source: Self-asserted source
Giancarlo Biagini via DimensionsWizard

Tropical Infectious Disease Consortium (TIDC) – Confidence in Concept 2019

2020-03-30 to 2022-03-29 | Grant
Medical Research Council (London, GB)
GRANT_NUMBER: MC_PC_19045
Source: Self-asserted source
Giancarlo Biagini via DimensionsWizard

Investigating the pharmacology of 8-Aminoquinoline antimalarial agents

2019-09 to 2024-03 | Grant
MRC (London, GB)
Part of GRANT_NUMBER:

2269400

GRANT_NUMBER:

MR/R015678/1

Source: Self-asserted source
Giancarlo Biagini

Tropical Infectious Disease Consortium: Expanding and Accelerating Product Development

2019-06-30 to 2021-03-30 | Grant
Medical Research Council (London, GB)
GRANT_NUMBER: MC_PC_18055
Source: Self-asserted source
Giancarlo Biagini via DimensionsWizard

MICA: New combination therapy against MDR TB targeting the respiratory chain

2019-03-01 to 2022-02-28 | Grant
Medical Research Council (London, GB)
GRANT_NUMBER: MR/S00467X/1
Source: Self-asserted source
Giancarlo Biagini via DimensionsWizard

MICA: New combination therapy against MDR TB targeting the respiratory chain

2018-03-30 to 2021-03-29 | Grant
Medical Research Council (London, GB)
GRANT_NUMBER: MC_PC_17225
Source: Self-asserted source
Giancarlo Biagini via DimensionsWizard

Tropical Infectious Disease Consortium: Expanding and Accelerating Product Development (LSTM P2D 2017)

2018-03-30 to 2019-09-29 | Grant
Medical Research Council (London, GB)
GRANT_NUMBER: MC_PC_17196
Source: Self-asserted source
Giancarlo Biagini via DimensionsWizard

Tropical Infectious Disease Consortium: Expanding and Accelerating ProductDevelopment

2018-03-01 to 2020-02-29 | Grant
Medical Research Council (London, GB)
GRANT_NUMBER: MC_PC_17167
Source: Self-asserted source
Giancarlo Biagini via DimensionsWizard

Tropical Infectious Disease Consortium: Expanding and Accelerating ProductDevelopment

2017-03-01 to 2019-02-28 | Grant
Medical Research Council (London, GB)
GRANT_NUMBER: MC_PC_16052
Source: Self-asserted source
Giancarlo Biagini via DimensionsWizard

Accelerating Product Development in Global Health

Source: Self-asserted source
Giancarlo Biagini via DimensionsWizard

Accelerating Product Development in Global Health

2017-03-01 to 2018-08-30 | Grant
Medical Research Council (London, GB)
GRANT_NUMBER: MC_PC_16078
Source: Self-asserted source
Giancarlo Biagini via DimensionsWizard

Understanding pharmacokinetic - pharmacodynamic determinants of outcome to inform dose optimisation for non-MDR TB re-treatment patients in Vietnam

2016-07-31 to 2019-01-31 | Grant
Medical Research Council (London, GB)
GRANT_NUMBER: MR/N028376/1
Source: Self-asserted source
Giancarlo Biagini via DimensionsWizard

Tropical Infectious Disease Consortium: Expanding and Accelerating Product Development

2016-03-01 to 2018-02-28 | Grant
Medical Research Council (London, GB)
GRANT_NUMBER: MC_PC_15040
Source: Self-asserted source
Giancarlo Biagini via DimensionsWizard

Tropical Infectious Disease Consortium: Sustaining, Expanding and Accelerating Product Development

2015-03-01 to 2016-08-30 | Grant
Medical Research Council (London, GB)
GRANT_NUMBER: MC_PC_14111
Source: Self-asserted source
Giancarlo Biagini via DimensionsWizard

Supporting excellence in basic and clinical research: A flow cytometry/sorting and cell imaging platform for the genotypic and phenotypic analysis of Hazard Group 3 pathogens.

Supporting excellence in basic and clinical research: A flow cytometry/sorting and cell imaging platform for the genotypic and phenotypic analysis of Hazard Group 3 pathogens.

2015-01-01 to 2019-12-31 | Grant
Wellcome Trust (London, GB)
GRANT_NUMBER:

104936/Z/14/Z

Source: Self-asserted source
Giancarlo Biagini via DimensionsWizard

Defining the mechanism of action of the 8-aminoquinolines: A pre-requisite to rationally designed safe antimalarials for the elimination era

2014-01-02 to 2017-01-01 | Grant
Medical Research Council (London, GB)
GRANT_NUMBER: MR/L000644/1
Source: Self-asserted source
Giancarlo Biagini via DimensionsWizard

MICA: Liverpool Imaging Partnership: Molecular physiology and drug response

2013-02-13 to 2017-02-12 | Grant
Medical Research Council (London, GB)
GRANT_NUMBER: MR/K015931/1
Source: Self-asserted source
Giancarlo Biagini via DimensionsWizard

LEAD SERIES DEVELOPMENT & OPTIMISATION OF A NEW DRUG AGAINST ACTIVE AND LATENT TUBERCULOSIS

2011-09-30 to 2014-03-30 | Grant
Medical Research Council (London, GB)
GRANT_NUMBER: G1002586
Source: Self-asserted source
Giancarlo Biagini via DimensionsWizard

Targeting the mitochondrial electron transport chain of malaria parasites: computer-assisted design and synthesis of bc1 complex inhibitors as antimalarial agents

2010-01-01 to 2013-06-30 | Grant
Foundation for Science and Technology (Lisbon, PT)
Source: Self-asserted source
Giancarlo Biagini via DimensionsWizard

Alternative complex I as a drug target in malaria

2008-11-01 to 2011-03-31 | Grant
Wellcome Trust (London, GB)
GRANT_NUMBER:

086061/Z/08/A

Source: Self-asserted source
Giancarlo Biagini via DimensionsWizard

Alternative complex I as a drug target in malaria

2008-11-01 to 2011-03-31 | Grant
Wellcome Trust (London, GB)
GRANT_NUMBER:

086061/Z/08/Z

Source: Self-asserted source
Giancarlo Biagini via DimensionsWizard

Ubiquinone in Giardia: Amitochondrial component in an amitochondriate parasite

Source: Self-asserted source
Giancarlo Biagini via DimensionsWizard

Ubiquinone in Giardia: Amitochondrial component in an amitochondriate parasite

2002-01-01 to 2003-12-31 | Grant
Australian Research Council (Canberra, AU)
GRANT_NUMBER: LX0214944
Source: Self-asserted source
Giancarlo Biagini via DimensionsWizard

Works (50 of 157)

Items per page:
Page 1 of 4

Assessment of Favipiravir and Remdesivir in Combination for SARS-CoV-2 Infection in Syrian Golden Hamsters

Viruses
2024-11 | Journal article | Author
Contributors: Megan Neary; Eduardo Gallardo-Toledo; Joanne Sharp; Joanne Herriott; Edyta Kijak; Chloe Bramwell; Helen Cox; Lee Tatham; Helen Box; Paul Curley et al.
Source: check_circle
Multidisciplinary Digital Publishing Institute

A feasibility study of controlled human infection with intradermal Bacillus Calmette–Guérin (BCG) injection: Pilot BCG controlled human infection model

Wellcome Open Research
2024-06-05 | Journal article
Part of ISSN: 2398-502X
Contributors: Emma Carter; Emma Carter; Dima El Safadi; Kondwani Jambo; Tinashe Kenny-Nyazika; Angela Hyder-Wright; Gift Chiwala; Tarsizio Chikaonda; Anthony E. Chirwa; Jonathan González-Sánchez et al.
Source: Self-asserted source
Giancarlo Biagini

A mycobacterial DNA extraction protocol designed for resource limited settings generates high quality whole genome sequencing

2024-06-01 | Preprint
Contributors: Caitlin Percy; Ilinca Memelis; Thomas Edwards; Adam P. Roberts; Giancarlo Biagini; Daire Cantillon
Source: check_circle
Crossref

Sequential Infection with Influenza A Virus Followed by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Leads to More Severe Disease and Encephalitis in a Mouse Model of COVID-19

Viruses
2024-05 | Journal article | Author
Contributors: Jordan J. Clark; Rebekah Penrice-Randal; Parul Sharma; Xiaofeng Dong; Shaun H. Pennington; Amy E. Marriott; Stefano Colombo; Andrew Davidson; Maia Kavanagh Williamson; David A. Matthews et al.
Source: check_circle
Multidisciplinary Digital Publishing Institute
grade
Preferred source (of 2)‎

A Quantitative Method for the Study of HIV-1 and Mycobacterium tuberculosis Coinfection

The Journal of infectious diseases
2023 | Journal article
EID:

2-s2.0-85149176745

Part of ISSN: 15376613
Contributors: Donnellan, S.; Pennington, S.H.; Ruggiero, A.; Martinez-Rodriguez, C.; Pouget, M.; Thomas, J.; Ward, S.A.; Pollakis, G.; Biagini, G.A.; Paxton, W.A.
Source: Self-asserted source
Giancarlo Biagini via Scopus - Elsevier

Identification of 2-Aryl-Quinolone Inhibitors of Cytochrome bd and Chemical Validation of Combination Strategies for Respiratory Inhibitors against Mycobacterium tuberculosis

ACS Infectious Diseases
2023 | Journal article
EID:

2-s2.0-85146188119

Part of ISSN: 23738227
Contributors: Jeffreys, L.N.; Ardrey, A.; Hafiz, T.A.; Dyer, L.-A.; Warman, A.J.; Mosallam, N.; Nixon, G.L.; Fisher, N.E.; Hong, W.D.; Leung, S.C. et al.
Source: Self-asserted source
Giancarlo Biagini via Scopus - Elsevier

Practical considerations for a TB controlled human infection model (TB-CHIM); the case for TB-CHIM in Africa, a systematic review of the literature and report of 2 workshop discussions in UK and Malawi

Wellcome Open Research
2023 | Journal article
EID:

2-s2.0-85153187796

Part of ISSN: 2398502X
Contributors: Gordon, S.B.; Sichone, S.; Chirwa, A.E.; Hazenberg, P.; Kafuko, Z.; Ferreira, D.M.; Flynn, J.; Fortune, S.; Balasingam, S.; Biagini, G.A. et al.
Source: Self-asserted source
Giancarlo Biagini via Scopus - Elsevier

Age-differential CD13 and interferon expression in airway epithelia affect SARS-CoV-2 infection - Effects of vitamin D.

Mucosal immunology
2023-09-01 | Journal article
Contributors: Sposito F; Pennington SH; David CAW; Duggan J; Sarah Northey; Biagini GA; Neill Liptrott; Amandine Charras; Paul McNamara; Christian Hedrich
Source: Self-asserted source
Giancarlo Biagini

Attaching protein-adsorbing silica particles to the surface of cotton substrates for bioaerosol capture including SARS-CoV-2.

Nature communications
2023-08-18 | Journal article | Author
Contributors: Collings K; Boisdon C; Tung-Ting Sham; Skinley K; Oh HK; Tessa Prince; Ahmed A; Pennington SH; Brownridge PJ; Thomas Edwards et al.
Source: Self-asserted source
Giancarlo Biagini

Quantitation of tizoxanide in multiple matrices to support cell culture, animal and human research.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
2023-07-16 | Journal article
Contributors: Megan Neary; Arshad U; Tatham L; Pertinez H; Box H; Rajoli RKR; Valentijn A; Joanne Sharp; Rannard SP; Biagini GA et al.
Source: Self-asserted source
Giancarlo Biagini

Lack of antiviral activity of probenecid in Vero E6 cells and Syrian golden hamsters: a need for better understanding of inter-lab differences in preclinical assays

bioRxiv
2022 | Other
EID:

2-s2.0-85128958421

Part of ISSN: 26928205
Contributors: Box, H.; Pennington, S.H.; Kijak, E.; Tatham, L.; Caygill, C.H.; Lopeman, R.C.; Jeffreys, L.N.; Herriott, J.; Sharp, J.; Neary, M. et al.
Source: Self-asserted source
Giancarlo Biagini via Scopus - Elsevier

Remdesivir–ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2

International Journal of Antimicrobial Agents
2022 | Journal article
EID:

2-s2.0-85125483914

Part of ISSN: 18727913 09248579
Contributors: Jeffreys, L.N.; Pennington, S.H.; Duggan, J.; Caygill, C.H.; Lopeman, R.C.; Breen, A.F.; Jinks, J.B.; Ardrey, A.; Donnellan, S.; Patterson, E.I. et al.
Source: Self-asserted source
Giancarlo Biagini via Scopus - Elsevier

An optimised method for the recovery of laboratory generated SARS-CoV-2 aerosols by plaque assay

2022-11-01 | Preprint
Contributors: Rachel L Byrne; Susan Gould; Thomas Edwards; Dominic Wooding; Barry Atkinson; Ginny Moore; Kieran Collings; Cedric Boisdon; Simon Maher; Giancarlo Biagini et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Targeting the Ubiquinol-Reduction (Qi) Site of the Mitochondrial Cytochrome bc1 Complex for the Development of Next Generation Quinolone Antimalarials

Biology
2022-07-25 | Journal article
Contributors: Kangsa Amporndanai; Nattapon Pinthong; Paul M. O’Neill; W. David Hong; Richard K. Amewu; Chandrakala Pidathala; Neil G. Berry; Suet C. Leung; Stephen A. Ward; Giancarlo A. Biagini et al.
Source: check_circle
Crossref
grade
Preferred source (of 3)‎

Enantioselective Synthesis and Profiling of Potent, Nonlinear Analogues of Antimalarial Tetraoxanes E209 and N205

ACS Medicinal Chemistry Letters
2021 | Journal article
EID:

2-s2.0-85110272370

Part of ISSN: 19485875
Contributors: Woodley, C.M.; Nixon, G.L.; Basilico, N.; Parapini, S.; Hong, W.D.; Ward, S.A.; Biagini, G.A.; Leung, S.C.; Taramelli, D.; Onuma, K. et al.
Source: Self-asserted source
Giancarlo Biagini via Scopus - Elsevier

Measurement of the Intracellular Mycobacterium tuberculosis Drug Effect and Prediction of the Clinical Dose–Response Relationship Using Intracellular Pharmacodynamic Modeling (PD<sub>i</sub>)

Methods in Molecular Biology
2021 | Book
EID:

2-s2.0-85105771770

Contributors: Donnellan, S.; Martínez-Rodríguez, C.; Aljayyoussi, G.; Biagini, G.A.
Source: Self-asserted source
Giancarlo Biagini via Scopus - Elsevier

SARS-CoV-2 infects an upper airway model derived from induced pluripotent stem cells

Stem Cells
2021 | Journal article
EID:

2-s2.0-85108543112

Part of ISSN: 15494918 10665099
Contributors: Djidrovski, I.; Georgiou, M.; Hughes, G.L.; Patterson, E.I.; Casas-Sanchez, A.; Pennington, S.H.; Biagini, G.A.; Moya-Molina, M.; van den Bor, J.; Smit, M.J. et al.
Source: Self-asserted source
Giancarlo Biagini via Scopus - Elsevier

Quantitation of tizoxanide in multiple matrices to support cell culture, animal and human research

2021-05-28 | Other
Contributors: Megan Neary; Usman Arshad; Lee Tatham; Henry Pertinez; Helen Box; Rajith KR Rajoli; Anthony Valentijn; Joanne Sharp; Steve P Rannard; Giancarlo A Biagini et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis

medRxiv
2020 | Other
EID:

2-s2.0-85098615321

Contributors: Rajoli, R.K.R.; Pertinez, H.; Arshad, U.; Box, H.; Tatham, L.; Curley, P.; Neary, M.; Sharp, J.; Liptrott, N.J.; Valentijn, A. et al.
Source: Self-asserted source
Giancarlo Biagini via Scopus - Elsevier

Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate plasma and target site concentrations derived from their established human pharmacokinetics

medRxiv
2020 | Other
EID:

2-s2.0-85099189941

Contributors: Arshad, U.; Pertinez, H.; Box, H.; Tatham, L.; Rajoli, R.K.R.; Curley, P.; Neary, M.; Sharp, J.; Liptrott, N.J.; Valentijn, A. et al.
Source: Self-asserted source
Giancarlo Biagini via Scopus - Elsevier

Sequential infection with influenza A virus followed by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to more severe disease and encephalitis in a mouse model of COVID-19

bioRxiv
2020 | Other
EID:

2-s2.0-85151881804

Contributors: Clark, J.J.; Penrice-Randal, R.; Sharma, P.; Kipar, A.; Dong, X.; Pennington, S.H.; Marriott, A.E.; Colombo, S.; Davidson, A.; Williamson, M.K. et al.
Source: Self-asserted source
Giancarlo Biagini via Scopus - Elsevier

The relative rate of kill of the MMV Malaria Box compounds provides links to the mode of antimalarial action and highlights scaffolds of medicinal chemistry interest

The Journal of antimicrobial chemotherapy
2020 | Journal article
EID:

2-s2.0-85078507086

Contributors: Ullah, I.; Sharma, R.; Mete, A.; Biagini, G.A.; Wetzel, D.M.; Horrocks, P.D.
Source: Self-asserted source
Giancarlo Biagini via Scopus - Elsevier

Remdesivir-Ivermectin combination displays synergistic interaction with improved in vitro antiviral activity against SARS-CoV-2

2020-12 | Preprint
OTHER-ID:

PPR257925

Contributors: Jeffreys L; Pennington SH; Duggan J; Breen A; Jinks J; Ardrey A; Donnellan S; Patterson EI; Hughes GL; Hong D et al.
Source: Self-asserted source
Giancarlo Biagini via Europe PubMed Central
grade
Preferred source (of 2)‎

Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2?

ACS infectious diseases
2020-12-22 | Journal article
Source: Self-asserted source
Giancarlo Biagini
grade
Preferred source (of 2)‎

Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis.

British journal of clinical pharmacology
2020-10 | Journal article
Contributors: Rajoli RKR; Pertinez H; Arshad U; Box H; Tatham L; Curley P; Neary M; Sharp J; Liptrott NJ; Valentijn A et al.
Source: Self-asserted source
Giancarlo Biagini via Europe PubMed Central
grade
Preferred source (of 2)‎

The cytochrome bc<sub>1</sub> complex as an antipathogenic target.

FEBS letters
2020-07 | Journal article
Contributors: Fisher N; Meunier B; Biagini GA
Source: Self-asserted source
Giancarlo Biagini via Europe PubMed Central
grade
Preferred source (of 2)‎

Potent Tetrahydroquinolone Eliminates Apicomplexan Parasites.

Frontiers in cellular and infection microbiology
2020-06 | Journal article
Contributors: McPhillie MJ; Zhou Y; Hickman MR; Gordon JA; Weber CR; Li Q; Lee PJ; Amporndanai K; Johnson RM; Darby H et al.
Source: Self-asserted source
Giancarlo Biagini via Europe PubMed Central
grade
Preferred source (of 2)‎

Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.

Clinical pharmacology and therapeutics
2020-06-14 | Journal article
Source: Self-asserted source
Giancarlo Biagini
grade
Preferred source (of 2)‎

Modelling of Systemic versus Pulmonary Chloroquine Exposure in Man for COVID-19 Dose Selection

2020-04-30 | Other
Contributors: Ghaith Aljayyoussi; Rajith KR Rajoli; Henry Pertinez; Shaun H Pennington; W. David Hong; Paul M. O’Neill; Andrew Owen; Steve A Ward; Giancarlo A Biagini
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Treatment responses to azithromycin and ciprofloxacin in uncomplicated Salmonella Typhi infection: A comparison of clinical and microbiological data from a controlled human infection model

PLoS Neglected Tropical Diseases
2019 | Journal article
EID:

2-s2.0-85077762231

Contributors: Jin, C.; Gibani, M.M.; Pennington, S.H.; Liu, X.; Ardrey, A.; Aljayyoussi, G.; Moore, M.; Angus, B.; Parry, C.M.; Biagini, G.A. et al.
Source: Self-asserted source
Giancarlo Biagini via Scopus - Elsevier

Antimalarial activity of primaquine operates via a two-step biochemical relay

Nature Communications
2019-12 | Journal article
Part of ISSN: 2041-1723
Source: Self-asserted source
Giancarlo Biagini
grade
Preferred source (of 2)‎

Intracellular Pharmacodynamic Modeling Is Predictive of the Clinical Activity of Fluoroquinolones against Tuberculosis

Antimicrobial Agents and Chemotherapy
2019-12-20 | Journal article
Contributors: Samantha Donnellan; Ghaith Aljayyoussi; Emmanuel Moyo; Alison Ardrey; Carmen Martinez-Rodriguez; Stephen A. Ward; Giancarlo A. Biagini
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Intracellular PD Modelling (PDi) for the Prediction of Clinical Activity of Increased Rifampicin Dosing

Pharmaceutics
2019-06-13 | Journal article
Part of ISSN: 1999-4923
Source: Self-asserted source
Giancarlo Biagini
grade
Preferred source (of 2)‎

Potent Antimalarial 2-Pyrazolyl Quinolone

ACS Med Chem Lett
2018 | Journal article
Contributors: David Hong, W.; Leung, S. C.; Amporndanai, K.; Davies, J.; Priestley, R. S.; Nixon, G. L.; Berry, N. G.; Samar Hasnain, S.; Antonyuk, S.; Ward, S. A. et al.
Source: Self-asserted source
Giancarlo Biagini via ResearcherID
grade
Preferred source (of 2)‎

Synthesis and profiling of benzylmorpholine 1,2,4,5-tetraoxane analogue N205: Towards tetraoxane scaffolds with potential for single dose cure of malaria

Bioorg Med Chem
2018 | Journal article
Contributors: O' Neill, P. M.; Stocks, P. A.; Sabbani, S.; Roberts, N. L.; Amewu, R. K.; Shore, E. R.; Aljayyoussi, G.; Angulo-Barturén, I.; Belén, M.; Jiménez-Díaz, et al.
Source: Self-asserted source
Giancarlo Biagini via ResearcherID
grade
Preferred source (of 2)‎

A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance.

Nature communications
2017-05 | Journal article
Source: Self-asserted source
Giancarlo Biagini via Europe PubMed Central
grade
Preferred source (of 3)‎

Rational Design, Synthesis, and Biological Evaluation of Heterocyclic Quinolones Targeting the Respiratory Chain of Mycobacterium tuberculosis.

Journal of medicinal chemistry
2017-05 | Journal article
Source: Self-asserted source
Giancarlo Biagini via Europe PubMed Central
grade
Preferred source (of 3)‎

Pharmacokinetic-Pharmacodynamic modelling of intracellular Mycobacterium tuberculosis growth and kill rates is predictive of clinical treatment duration

Scientific Reports
2017-03-29 | Journal article
Contributors: Ghaith Aljayyoussi; Victoria A. Jenkins; Raman Sharma; Alison Ardrey; Samantha Donnellan; Stephen A. Ward; Giancarlo A. Biagini
Source: check_circle
Crossref
grade
Preferred source (of 3)‎

OptiMal-PK: an internet-based, user-friendly interface for the mathematical-based design of optimized anti-malarial treatment regimens.

2016 | Journal article
Contributors: Aljayyoussi G; Kay K; Ward SA; Biagini GA
Source: Self-asserted source
Giancarlo Biagini via Europe PubMed Central
grade
Preferred source (of 2)‎

A validated bioluminescence-based assay for the rapid determination of the initial rate of kill for discovery antimalarials.

2016-12 | Journal article
Contributors: Ullah I; Sharma R; Biagini GA; Horrocks P
Source: Self-asserted source
Giancarlo Biagini via Europe PubMed Central
grade
Preferred source (of 3)‎

Corrigendum: A Click Chemistry-Based Proteomic Approach Reveals that 1,2,4-Trioxolane and Artemisinin Antimalarials Share a Common Protein Alkylation Profile.

Angewandte Chemie (International ed. in English)
2016-08 | Journal article
Source: Self-asserted source
Giancarlo Biagini via Europe PubMed Central
grade
Preferred source (of 2)‎

A Click Chemistry-Based Proteomic Approach Reveals that 1,2,4-Trioxolane and Artemisinin Antimalarials Share a Common Protein Alkylation Profile.

2016-05 | Journal article
Contributors: Ismail HM; Barton VE; Panchana M; Charoensutthivarakul S; Biagini GA; Ward SA; O'Neill PM
Source: Self-asserted source
Giancarlo Biagini via Europe PubMed Central

A Click Chemistry-Based Proteomic Approach Reveals that 1,2,4-Trioxolane and Artemisinin Antimalarials Share a Common Protein Alkylation Profile.

2016-05 | Journal article
Contributors: Ismail HM; Barton VE; Panchana M; Charoensutthivarakul S; Biagini GA; Ward SA; O'Neill PM
Source: Self-asserted source
Giancarlo Biagini via Europe PubMed Central
grade
Preferred source (of 2)‎

Artemisinin activity-based probes identify multiple molecular targets within the asexual stage of the malaria parasites Plasmodium falciparum 3D7.

2016-02 | Journal article
Contributors: Ismail HM; Barton V; Phanchana M; Charoensutthivarakul S; Wong MH; Hemingway J; Biagini GA; O'Neill PM; Ward SA
Source: Self-asserted source
Giancarlo Biagini via Europe PubMed Central
grade
Preferred source (of 2)‎

2-Pyridylquinolone antimalarials with improved antimalarial activity and physicochemical properties

Medchemcomm
2015 | Journal article
WOSUID:

WOS:000357786200004

Contributors: Charoensutthivarakul, Sitthivut; Hong, W. David; Leung, Suet C.; Gibbons, Peter D.; Bedingfield, Paul T. P.; Nixon, Gemma L.; Lawrenson, Alexandre S.; Berry, Neil G.; Ward, Stephen A.; Biagini, Giancarlo A. et al.
Source: Self-asserted source
Giancarlo Biagini via ResearcherID
grade
Preferred source (of 2)‎

Antimalarial 4(1H)-pyridones bind to the Q(i) site of cytochrome bc(1)

Proceedings of the National Academy of Sciences of the United States of America
2015 | Journal article
WOSUID:

WOS:000348040700042

Contributors: Capper, Michael J.; O'Neill, Paul M.; Fisher, Nicholas; Strange, Richard W.; Moss, Darren; Ward, Stephen A.; Berry, Neil G.; Lawrenson, Alexandre S.; Hasnain, S. Samar; Biagini, Giancarlo A. et al.
Source: Self-asserted source
Giancarlo Biagini via ResearcherID
grade
Preferred source (of 2)‎

Carbamoyl Triazoles, Known Serine Protease Inhibitors, Are a Potent New Class of Antimalarials

Journal of Medicinal Chemistry
2015 | Journal article
WOSUID:

WOS:000360415800011

Contributors: McConville, Matthew; Fernandez, Jorge; Angulo-Barturen, Inigo; Bahamontes-Rosa, Noemi; Ballell-Pages, Lluis; Castaneda, Pablo; de Cozar, Cristina; Crespo, Benigno; Guijarro, Laura; Belen Jimenez-Diaz, Maria et al.
Source: Self-asserted source
Giancarlo Biagini via ResearcherID
grade
Preferred source (of 2)‎

Novel inhibitors of the Plasmodium falciparum electron transport chain

Parasitology
2014 | Journal article
Contributors: Stocks, P. A.; Barton, V.; Antoine, T.; Biagini, G. A.; Ward, S. A.; O'Neill, P. M.
Source: Self-asserted source
Giancarlo Biagini via ResearcherID

Rapid kill of malaria parasites by artemisinin and semi-synthetic endoperoxides involves ROS-dependent depolarization of the membrane potential

Journal of Antimicrobial Chemotherapy
2014 | Journal article
DOI:

10.1093/jac/dkt486

Contributors: Antoine, Thomas; Fisher, Nicholas; Amewu, Richard; ONeill, Paul M.; Ward, Stephen A.; Biagini, Giancarlo A.
Source: Self-asserted source
Giancarlo Biagini via ResearcherID
grade
Preferred source (of 2)‎

Sex, power and drugs: the murky world of malaria parasite mitochondria.

2014 | Journal article
Contributors: Biagini G
Source: Self-asserted source
Giancarlo Biagini via Europe PubMed Central
Items per page:
Page 1 of 4

Peer review (4 reviews for 1 publication/grant)

Review activity for UK Research and Innovation (4)